These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8146549)

  • 21. [Treatment guidelines of chronic myeloid leukemia].
    Chinese Society of Hematology
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):426-32. PubMed ID: 21781508
    [No Abstract]   [Full Text] [Related]  

  • 22. [Chronic myeloid leukemia. Current strategies in diagnosis, therapy and follow-up].
    Hochhaus A; Hehlmann R
    Internist (Berl); 1996 Oct; 37(10):1013-21. PubMed ID: 9019445
    [No Abstract]   [Full Text] [Related]  

  • 23. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
    Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
    Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytogenetics of chronic myeloid leukaemia.
    Chase A; Huntly BJ; Cross NC
    Best Pract Res Clin Haematol; 2001 Sep; 14(3):553-71. PubMed ID: 11640869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
    Prejzner W
    Med Sci Monit; 2002 May; 8(5):BR193-7. PubMed ID: 12011769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
    Colla S; Sammarelli G; Voltolini S; Crugnola M; Sebastio P; Giuliani N
    Haematologica; 2004 May; 89(5):611-3. PubMed ID: 15136228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Philadelphia negative, Bcr-Abl positive chronic myeloid leukemia associated with pure red cell aplasia.
    Karti S; Yilmaz M; Sonmez M; Akdogan R; Ersoz S; Ucar F; Ovali E
    J Exp Clin Cancer Res; 2003 Jun; 22(2):341-2. PubMed ID: 12866588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diagnosis and differential diagnosis of chronic myeloid leukemia].
    Bessmel'tsev SS; Rukavitsyn OA; Abdulkadyrov KM
    Vopr Onkol; 2001; 47(5):544-51. PubMed ID: 11785093
    [No Abstract]   [Full Text] [Related]  

  • 29. Chronic myeloid leukemia in 2006: a perspective.
    Mauro MJ; Deininger MW
    Haematologica; 2006 Feb; 91(2):152. PubMed ID: 16461297
    [No Abstract]   [Full Text] [Related]  

  • 30. [Molecular basis of chronic myelogenous leukemia and significance of diagnostic methods based on BCR-ABL gene amplification].
    Sacha T; Dulak J; Skotnicki AB; Dembińska-Kiec A
    Przegl Lek; 1999; 56 Suppl 1():57-61. PubMed ID: 10494184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease in chronic myeloid leukaemia.
    Cross NC
    Hematol Cell Ther; 1998 Oct; 40(5):224-8. PubMed ID: 9844816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
    Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now.
    Mauro MJ
    Haematologica; 2005 Mar; 90(3):291B. PubMed ID: 15749655
    [No Abstract]   [Full Text] [Related]  

  • 34. Age at diagnosis of chronic myeloid leukaemia.
    Ng SC; Kuperan P
    Malays J Pathol; 1990 Dec; 12(2):111. PubMed ID: 2102966
    [No Abstract]   [Full Text] [Related]  

  • 35. Age at diagnosis of chronic myeloid leukaemia.
    Hamidah NH; Cheong SK; Ainoon O; Hoe TS
    Malays J Pathol; 1991 Dec; 13(2):123. PubMed ID: 1842907
    [No Abstract]   [Full Text] [Related]  

  • 36. The detection and significance of minimal residual disease in chronic myeloid leukemia.
    Radich JP
    Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
    Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
    Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
    Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic myeloid leukemia presenting with avascular necrosis of femur head.
    Gupta D; Gaiha M; Siddaraju N; Daga MK; Anuradha S
    J Assoc Physicians India; 2003 Feb; 51():214-5. PubMed ID: 12725271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring of minimal residual disease using WT1 assay for patients with chronic myeloid leukemia who undergo allogeneic stem cell transplantation.
    Tamaki H; Ogawa H
    Bone Marrow Transplant; 2004 Oct; 34(7):653-4. PubMed ID: 15258561
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.